Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy men or women between the ages of 18 and 45 years old~Exclusion Criteria:~* History (including family history) or symptoms of, or risk factors for bleeding~* History (including family history) of or risk factors for a hypercoagulable or thrombotic condition~* Absolute/relative contraindication to anticoagulation or treatment with specific anticoagulants~* History of major surgery, severe trauma or bone fracture within 3 months prior to dosing; or planned surgery within 1 month after dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Module 4 (600 mg bolus) (Type: EXPERIMENTAL): 600 mg PRT064445 given as a single IV bolus
- Module 4 (800 mg bolus + 480 mg infusion) 8mg/min (Type: EXPERIMENTAL): 1280 mg PRT064445: 800 mg IV at \~30 mg/min, followed by a continuous infusion of 480 mg (4 mg /min over 60 minutes)
- Module 4 (800 mg bolus) (Type: EXPERIMENTAL): 800 mg PRT064445 as a single IV bolus
- Module 4 Placebo (Type: PLACEBO_COMPARATOR): Placebo administered intravenously (IV) as a bolus or a bolus followed by continuous infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).